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The Learning Health System (LHS) describes linking routine healthcare systems directly with both research translation and
knowledge translation as an extension of the evidence-based medicine paradigm, taking advantage of the ubiquitous use of
electronic health record (EHR) systems. TRANSFoRm is an EU FP7 project that seeks to develop an infrastructure for the LHS
in European primary care. Methods. The project is based on three clinical use cases, a genotype-phenotype study in diabetes,
a randomised controlled trial with gastroesophageal reflux disease, and a diagnostic decision support system for chest pain,
abdominal pain, and shortness of breath. Results. Four models were developed (clinical research, clinical data, provenance, and
diagnosis) that form the basis of the projects approach to interoperability. These models are maintained as ontologies with binding
of terms to define precise data elements. CDISC ODM and SDM standards are extended using an archetype approach to enable a
two-level model of individual data elements, representing both research content and clinical content. Separate configurations of the
TRANSFoRm tools serve each use case. Conclusions.The project has been successful in using ontologies and archetypes to develop
a highly flexible solution to the problem of heterogeneity of data sources presented by the LHS.
1. Introduction
The Learning Health System (LHS) describes an approach to
improve healthcare that is solidly founded on the creation
and use of knowledge; “health” as opposed to “healthcare”
is sometimes used to emphasise the role of consumers as
cocreators and users of health knowledge [1]. The devel-
opment of the LHS is a natural outcome of the evolution
of evidence-based medicine (EBM). Based on the greater
utilisation of electronic health records (EHRs) and on novel
computing paradigms for data analysis, the LHS provides
potential solutions for the glacial slowness of both the
traditional research process and the research translation into
improved care [2].
EBM is focused on generating medical evidence and
using it to make clinical decisions. The highest level of
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evidence, level 1 evidence of the effectiveness of a health-
care intervention in EBM, consists of a meta-analysis of
randomised controlled trials (RCTs) [3]. However, RCTs are
complex and extremely expensive, the result being that much
of healthcare remains unsupported by high quality evidence.
Furthermore, RCTs themselves are prone to bias and manip-
ulation in the choice of eligible subjects, comparators, and
outcome measures [4]. One solution has been to carry out
light touch and simple, termed “pragmatic” RCTs with very
inclusive eligibility criteria and followup via routine data
collection. It is those kinds of RCTs that lend themselvesmost
to incorporation into a LHS.
There is also potential to replace RCTs with analysis of
routine data, using techniques such as instrumental variables
and propensity scores to control for bias [5]. Much future
research is needed to define when routine data could be a
sufficient answer to a problem and when an RCT is required.
Furthermore, healthcare practice is not solely limited to inter-
ventions, but diagnosis and prognostication play essential
parts and are underpinned by prospective cohort evidence.
Again, routine data could play a significant role in replacing
time-consuming and costly cohort designs.
Primary healthcare is the first point of contact with health
services of patients with undifferentiated problems and also
provides continuing care for patients with chronic diseases
and follows families from “cradle to grave.” These functions
present a particular problem for EBM. The vast majority
of research, be it diagnostic or intervention based, takes
place in specialist centres and in highly selected populations
[6]. Diagnostic features are not portable across populations
with different prevalence and spectrum of disease. Likewise,
patients in RCTs are younger and fitter, take fewer drugs
concurrently, and have less comorbidity than typical primary
care populations. Therefore, many RCTs suffer from limited
external validity [7].
Even if appropriate research evidence exists, it is unlikely
to be available at the point of care. Early formulations of
EBM typically applied to the highly motivated clinician who
formulates questions during clinical practice and searches
for evidence. Indeed, Professor Sackett’s team at Oxford
developed an “evidence cart” for ward rounds, with a copy
for MEDLINE and a projector to assist in this process in real
time [8]. Over the subsequent years, the process of knowledge
translation has become formalised: guidelines are explicitly
built on systematic reviews of the best available evidence and
are refined down to a series of statements to support clinical
care, with an associated level of supporting evidence and
strength of recommendation [9]. However, even in countries
like the UK, where a national agency (National Institute
for Health and Care Excellence) is funded to carry out this
process, guidelines may only be updated once in a decade.
Increasingly, the number of potential guidelines applicable to
a given patient at a given point on the care pathway becomes
a problem of memory and prioritisation for the clinician, let
alone the patient. The LHS offers a potential means of using
highly advanced electronic triggers to help with advising
when one treatment or diagnosis is favoured. It should also be
possible to reintroduce patient choice by explicit weighting of
options using patient-derived outcome data.
The LHS concept is still in its infancy, and much needs to
be done to explore and demonstrate the potential for using an
advanced digital infrastructure to support the LHS. The FP7
TRANSFoRm project (http://www.transformproject.eu/)
was funded via the Patient Safety Stream of ICT for Health.
Efficient research design and knowledge translation are a
core underpinning of safe clinical practice. It is not good
enough to simply avoid error, defined as care that falls
well below the average standard, but clinicians should be
seeking optimal care for their patients. The LHS, at its
barest essential, is all about promoting optimal care. The
TRANSFoRm project aimed to develop and demonstrate
methods, models, standards, and a digital infrastructure for
three specific components of the LHS:
(1) genotype-phenotype epidemiological studies using
multiple existing primary care and “biobank”
genomic datasets;
(2) RCTs with both data and trial processes embedded
within the functionality of EHRs and the ability to col-
lect Patient Reported Outcome Measures (PROMs)
on demand;
(3) decision support for diagnosis, based on clinical
prediction rules (best diagnostic evidence) and fully
integrated with a demonstrator EHR system.
2. Methods
Each specific clinical “use case” (shown below) served four
purposes: initial requirements elicitation; detailed modelling
of infrastructure and required data elements; design of con-
current validation and evaluation studies; and final clinical
demonstrations. 21 partner organisations in ten EU member
states took part in the project, over five years. At the time
of writing, the project has 11 months to run and the final
evaluation and clinical studies are about to commence.
TRANSFoRm Use Cases
Diabetes Use Case. The aim of the Diabetes use case is to
enable a distributed query to look for eligible patients and
extract data from multiple federated databases. In the pilot
study, the query will define patients and data to support
analysis of the relationship between well-selected single
nucleotide polymorphisms (SNPs) in type 2 diabetic patients
and the response to sulfonylurea.
GORD Use Case. The aim of the GORD use case is to
investigate the effectiveness of on demand versus continuous
use of proton pump inhibitors on reflux symptoms, quality of
life, and self-rated health in patients with gastrooesophageal
reflux disease in primary care. The study will be conducted
in five localities (UK: two vendors, Poland, Netherlands, and
Crete) and it will aim to recruit, randomise, and follow 700
patients at 40 primary care centres using the clinical trial
application.
Diagnosis Use Case. The aim of the diagnosis use case is to
provide integrated point-of-care decision support for patients
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presenting with chest pain, abdominal pain, and shortness of
breath.
TRANSFoRm aims to produce a highly flexible infras-
tructure that presents the lowest possible barriers to entry
for EHR systems and datasets, but at the same time it
makes the maximum use of the existing data standards and
methods for managing heterogeneity, both structural and
terminological, between data sources. A basic principle of
the TRANSFoRm project was to use available standards
and models as much as possible and integrate them into
the TRANSFoRm infrastructure. It was decided early on in
the project that TRANSFoRm would take a model-based
approach, using 4 models to capture (1) clinical meaning,
(2) research meaning, (3) provenance, and (4) diagnostic
meaning. The latter is essentially a subset of the clinical
model, but it was modelled separately for efficiency. The
archetype approach of constraining one model against the
other, in a two-level design (clinical and research), was used
to describe data elements [10]. Where available, existing tools
for building and maintaining models as an ontology were
used, although we presented a novel use of LexEVS, which
we employed to support both structural and semanticmodels
[11].
Clinical concepts were modelled using an ontology
(termed the Clinical Data Information Model, CDIM) [12].
Additional semantic detail for data elements was expressed
by using LexEVS to support binding of terminology terms to
CDIM expressions. For representation of research processes,
we extended an existing domain model, the Primary Care
Research Object Model, adding objects primarily in the
clinical area [13].The resulting Clinical Research Information
Model (CRIM), in conjunction with CDIM, enabled a two-
level archetype to be defined for each required data element
in the use cases. In order to define case report forms and
study designs for the RCT, we used the CDISC ODM and
SDM standards, but adding an archetype approach for the
description of the data element “payload” [14].
The intention from the outset with TRANSFoRmwas that
all models would be published, standards would be reused
and adapted as required, the softwarewould reuse the existing
open source components, if available, and all TRANSFoRm
software components would bemade available as open source
tools under an “Apache” license. We believe that the value
lies in the data and the knowledge generated from it and
that amortizing the infrastructure can only act as a potential
barrier for realising the value of the data/knowledge.
Evaluation of TRANSFoRm will consist of a technical
validation of the TRANSFoRm tools and three clinical and
sociotechnical evaluation studies. For the DSS, an evaluation
of the system, integrated with the In Practice Systems Vision
3 EHR system, is underway. General practitioners are con-
ducting a simulated clinical session with actors simulating
patients presenting with carefully prepared test problems.
This is a within-subjects design, with the cases solved first
without and then with the DSS and the primary outcome
being accuracy. We also measure usability and amount of
information coded into the EHR. The Diabetes use case is
being evaluated on the basis of performance, as judged by
users, of the system in selecting and extracting data from
five databases. Accuracy of selecting eligible patients by
users employing the TRANSFoRm Query Workbench will
be measured. The GORD (gastrooesophageal reflux disease,
a disorder caused by the retrograde flow of gastric contents
from the stomach into the oesophagus, causing symptoms
and/or mucosal damage) study is being conducted as a
full clinical RCT (individual subjects randomised) with a
nested evaluation study. Principal outcomes of the clinical
study are symptom profiles and quality of life measured
by PROMs (Patient Reported Outcome Measures) collected
on smartphones via a dedicated TRANSFoRm mobile data
collection app. The sociotechnical evaluation is a nested
cluster trial andwill compare recruitment rates, completeness
of data, and costs of the TRANSFoRm system compared
to usual practice, in this case, a simple web form for the
clinical measures and paper questionnaires for the PROMs.
The results of the three TRANSFoRm evaluation studies will
be available in late 2015.
3. Results
The TRANSFoRm software ecosystem is comprised of a
set of generic middleware components that provide essen-
tial shared functions for the LHS applications built in
TRANSFoRm, namely, secure data transport, authentication,
semantic mediation, and data provenance (with respect
to processing of data within TRANSFoRm). As LHS is
characterized by routine production, transformation, and
dissemination of data and knowledge, secure channels and
reliable authentication are necessary to ensure confidence
and buy-in by the data owners. The data itself resides in
a vast array of distributed repositories that vary both in
structure and in terminology, making data interoperabil-
ity a key requirement that TRANSFoRm delivers using a
semantic mediation approach combined with the standard
data connectivity module (data node connector: DNC). The
DNC implements data interoperability, as well as managing
workflow processes and data extraction for participating
EHRs and data sources, as discussed in the next section.
Different flavours of DNC operate in epidemiology and
RCT use cases, as the RCT DNC has to support additional
requirements of the RCT workflow. Data provenance capture
in TRANSFoRm implements traceability, which is necessary
both to support trust and transparency and to enable learning
and improvement in LHS processes.
On top of these shared components, three application
specific tools were built to support the use cases: epidemio-
logical study query workbench, clinical trial monitoring tool,
and a diagnostic support plugin for EHR systems.
The high-level overview of the software components is
shown in Figure 1.
4. Epidemiological Study Application
The epidemiological study TRANSFoRm software configura-
tion (Figure 2) is used in the genotypic-phenotypic T2D study
use case and consists of tools for secure, provenance-enabled
design and execution of eligibility queries and data extrac-
tions from heterogeneous data sources. Eligibility queries are
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Figure 1: High-level software components.
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Figure 2: Epidemiological study configuration annotated with steps in the query process.
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Figure 3: TRANSFoRm Query Workbench.
Figure 4: Concept search in TRANSFoRm Query Workbench.
formulated by the researcher in the query workbench (QWB)
web tool (Figure 3) using model-based constructs (Figure 2,
step 1). QWB users enter clinical terms into the system
which then presents the user with a list of corresponding
concepts from standard terminologies and classifications
(Figure 4). The researchers are able to use a data quality
tool, storing metadata about available practices and data that
reside in them, to restrict the search to practices with a high
registration percentage of the variables targeted in the study
(step 2). The queries are dispatched to the data sources via
the middleware (step 3) to the local data node connector.
This is a TRANSFoRm component that sits at the data source
and translates the generic CDIM-based query into a local
representation using the semantic mediator component (step
4) and subsequently presents that locally interpretable query
either to the data source directly or to a human agent for final
approval (step 5), before returning the result. Three types of
queries are supported: patient counts, flagging patients, and
data extraction. Results of count and flag queries are sent back
to the query workbench via the middleware (step 6a) and
can be viewed by the researcher in the QWB web tool. The
patient data extraction result is passed to a safe haven (step
6b), accessible only to the authorised researcher, using the
appropriate secure data transport mechanism.
5. Clinical Trial Application
The clinical trial software configuration (Figure 5) is used
in the GORD use case and consists of components needed
for design, deployment, and collection of trial data, backed
by provenance and secure authentication framework for
researchers. The trial data collection is supported using
electronic Case Report Forms (eCRFs) and Patient Reported
Outcome Measures (PROMs). The former are filled in via a
web browser by the clinician, while the latter are completed
by the patients using either web or mobile devices. Also
supported is the orchestration of data collection across
multiple clinical sites where the trials are taking place.
The TRANSFoRm architecture delivers important com-
ponents of clinical trials: patient eligibility checks and enrol-
ment, prepopulation of eCRF data from EHRs, PROM data
collection from patients, and storing of a copy of study data
in the EHR. The key component of the architecture is the
TRANSFoRm Study System (TSS) that coordinates study
events and data collections, usingHTML form templates with
bound queries for preloading data from the EHR.The studies,
represented using a custom extension of CDISC SDM/ODM
standard, are loaded into the TRANSFoRm Study System
(step 1). Whenever an interaction is required between the
Study System and EHR, for example, eligibility checks or
partial filling of eCRF forms form EHR data, a query is fired
off to the EHR via the data node connector (step 2). As in
the epidemiological study configuration, the DNC acts as a
single point of contact of TRANSFoRm components and the
local EHR. In addition to translating and sending queries to
the EHR (step 3), the DNC acts as a web server that displays
eCRF forms for the clinician to fill with study-required
information not present in the EHR. Once completed, the
form is submitted to both the study database and the EHR
for storage considering requirements for eSource data use in
clinical trials (step 4). The message protocol for this inter-
action is currently undergoing comparison evaluation with
the IHE standards [17]. The PROM data is collected directly
from the patients using web or mobile devices (step 5). The
software configuration for the GORD study undergoes a
formal Computer SystemValidation (CSV) process including
qualifications for installation, operation, and performance to
ensure that study system and study process have been Good
Clinical Practice- (GCP-) validated prior to being employed
in the GORD clinical trial use case. Because of the narrow
connection between EHR and study system, part of GCP-
validation is the assurance of data privacy and confidentiality
of the personal patient data.
6. Diagnostic Support Application
Diagnostic support software configuration (Figure 6: diag-
nostic support configuration) consists of tools for mining
new rules from health data sources and managing their
deployment into the knowledge base, upon which an evi-
dence service is operating to drive a diagnostic support tool
embedded into a local EHR system.
The primary function of the tool is to suggest to clinicians
diagnoses to consider at the start of the clinical encounter
based only on the existing information in the patient record
and the current reason for encounter [18]. It also allows
bottom-up input of observed patient cues (symptoms and
signs), independent of associated diagnosis, or top-down
6 BioMed Research International
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Figure 6: Diagnostic support configuration.
drilling into and selection of cues supporting specific diag-
noses.
The rules used in the diagnostic process are generated
by data mining tasks (step 0), which get manually curated
and fed through the evidence service into the Clinical
Evidence Repository. When the patient presents, the cues
entered or selected are then used to dynamically rank the
potential differential diagnoses (Figure 7). This is done by
the DSS plugin embedded into the EHR, sending data to the
evidence service (step 1), which queries the rules stored in
BioMed Research International 7
Table 1: A table of outputs and exploitation plans.
TRANSFoRm output Exploitation plan
(1) Privacy model: a “zone” model with an explicit method of graphically depicting the
zones and operation of filters between zones Published method [15]
(2) Provenance infrastructure: based on the Open Provenance Model [REF], each
infrastructure component captures a provenance trace that enables reconstruction of an
audit trail for any given data element
Published method [16]
(3) Clinical prediction rule ontology based web service
The diagnostic ontology has been made
available as a public download in OWL
format on the TRANSFoRm website
(http://www.transformproject.eu/). A future
project is required to extend the data beyond
the three initial reasons for encounter
(4) Research data model
CDIM [12] and CRIM [13] have been
published. A full description of the use of
CDIM and CRIM in the construction of
data node connectors will be published and
made available on the TRANSFoRm website
(5) eCRF
Extension of CDISC ODM and SDM by the
incorporation of archetypes with references
to the CRIM and CDIMmodels will be
published and discussions are ongoing with
CDISC regarding future incorporation into
the standards. A reference implementation
of the clinical trial system will be maintained
within the European Institute. At present,
individual archetypes have to be written by
hand; discussions are in hand for the
production of an archetype authoring tool
(6) Data federation
A reference implementation of the
genotype-phenotype study system will be
maintained within the European Institute.
Search authoring tools will be available open
source
(7) DSS integration
The DSS is currently integrated with the
InPS Vision 3 system. Further work is
required to move this to a data node
connector/CDIM-based flexible system
Figure 7: Diagnostic support tool implemented as a plugin to InPS
Vision EHR system.
the Clinical Evidence Repository (step 2), before sending the
potential diagnoses back, annotated with levels of support
and confidence for the presenting case. Upon exiting the tool,
the coded evidence cues and current working diagnosis can
be saved back to the patient EHR (step 3).
7. Conclusions
TRANSFoRm demonstrated how a Learning Health System
can be implemented in European clinical research and prac-
tice. The full list of project outputs and the exploitation plan
for each are shown in Table 1 and promoted via an open
source model. TRANSFoRm will be a full participant in the
European Institute for Innovation through Health Data and
will make its tools and models available via the institute. In
addition, we are internationally active as participants and
promoters of the Learning Healthcare System. Via the LHS,
we are publishing models, standards, and tools to the world
research community. The UK serves as an exemplar of our
business model, with multiple EHRs participating in the
project aswell as theMedicines andHealthcare Products Reg-
ulatory Agency, Clinical Practice Research Datalink (CPRD).
CPRD currently extracts data from practices to a total popu-
lation of 8 million and links them to 20 other health datasets.
CPRD will be using the TRANSFoRm clinical trial tools,
in conjunction with additional reworking by a commercial
8 BioMed Research International
software vendor to create a full EHR-embedded clinical trial
facility for the UK Clinical Research Network.
Disclaimer
Theviews expressed are those of the authors andnot necessar-
ily those of the NHS, the NIHR, or the Department of Health.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This project has received funding from the European Union’s
Seventh Framework Programme for research, technological
development and demonstration under Grant Agreement
no. 247787. Additional support was received by the National
Institute for Health Research (NIHR) Biomedical Research
Centre at Guy’s and St Thomas’ NHS Foundation Trust and
King’s College London.
References
[1] C. Friedman, J. Rubin, J. Brown et al., “Toward a science of
learning systems: a research agenda for the high-functioning
Learning Health System,” Journal of the American Medical
Informatics Association, vol. 22, no. 1, pp. 43–50, 2015.
[2] C. P. Friedman, A. K. Wong, and D. Blumenthal, “Achieving
a nationwide learning health system,” Science Translational
Medicine, vol. 2, no. 25, Article ID 57cm29, 2010.
[3] D. L. Sackett, W. M. Rosenberg, J. A. Gray, R. B. Haynes, andW.
S. Richardson, “Evidence based medicine: what it is and what it
isn’t,” British Medical Journal, vol. 312, no. 7023, pp. 71–72, 1996.
[4] T.-P. Van Staa, B. Goldacre, M. Gulliford et al., “Pragmatic ran-
domised trials using routine electronic health records: putting
them to the test,” British Medical Journal, vol. 344, no. 7843,
article e55, 2012.
[5] R. L. Tannen, M. G. Weiner, and S. M. Marcus, “Simulation
of the Syst-Eur randomized control trial using a primary care
electronic medical record was feasible,” Journal of Clinical
Epidemiology, vol. 59, no. 3, pp. 254–264, 2006.
[6] B. Delaney, “Primary care research in the postmodern world,”
Family Practice, vol. 21, no. 2, pp. 123–124, 2004.
[7] M. Fortin, J. Dionne, G. Pinho, J. Gignac, J. Almirall, and L.
Lapointe, “Randomized controlled trials: do they have external
validity for patients with multiple comorbidities?” The Annals
of Family Medicine, vol. 4, no. 2, pp. 104–108, 2015.
[8] D. L. Sackett, “Finding and applying evidence during clinical
rounds—the ‘evidence cart’,”The Journal of the American Medi-
cal Association, vol. 280, no. 15, pp. 1336–1338, 1998.
[9] M. K. Goldstein, R. W. Coleman, S. W. Tu et al., “Translating
research into practice: organizational issues in implementing
automated decision support for hypertension in three medical
centers,” Journal of the American Medical Informatics Associa-
tion, vol. 11, no. 5, pp. 368–376, 2004.
[10] D. Kalra, T. Beale, and S. Heard, The openEHR Foundation,
vol. 115 of Studies in Health Technology and Informatics, 2005,
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&dopt=Citation&list uids=16160223.
[11] J.-F. Ethier, O. Dameron, V. Curcin et al., “A unified struc-
tural/terminological interoperability framework based on lex-
EVS: application to TRANSFoRm,” Journal of the American
Medical Informatics Association, vol. 20, no. 5, pp. 986–994,
2013.
[12] J.-F. Ethier, V. Curcin, A. Barton et al., “Clinical data integra-
tion model. Core interoperability ontology for research using
primary care data,”Methods of Information in Medicine, vol. 54,
no. 1, pp. 16–23, 2014.
[13] W. Kuchinke, T. Karakoyun, C. Ohmann et al., “Extension of
the primary care research object model (PCROM) as clinical
research information model (CRIM) for the ‘learning health-
care system’,” BMC Medical Informatics and Decision Making,
vol. 14, no. 1, article 118, 2014.
[14] S. Garde, E.Hovenga, J. Buck, and P. Knaup, “Expressing clinical
data sets with openEHR archetypes: a solid basis for ubiquitous
computing,” International Journal of Medical Informatics, vol.
76, pp. S334–S341, 2007.
[15] W. Kuchinke, C. Ohmann, R. A. Verheij et al., “A standardised
graphic method for describing data privacy frameworks in
primary care research using a flexible zonemodel,” International
Journal of Medical Informatics, vol. 83, no. 12, pp. 941–957, 2014.
[16] V. Curcin, S. Miles, R. Danger, Y. Chen, R. Bache, and A.
Taweel, “Implementing interoperable provenance in biomedical
research,” Future GenerationComputer Systems, vol. 34, pp. 1–16,
2014.
[17] IHE, “IHEQuality,Research, andPublicHealthTechnical Frame-
work Supplement. Structured Data Capture,” http://www.ihe
.net/uploadedFiles/Documents/QRPH/IHE QRPH Suppl SDC
.pdf.
[18] O. Kostopoulou, A. Rosen, T. Round, E. Wright, A. Douiri, and
B. Delaney, “Early diagnostic suggestions improve accuracy of
GPs: a randomised controlled trial using computer-simulated
patients,” British Journal of General Practice, vol. 65, no. 630, pp.
e49–e54, 2014.
Submit your manuscripts at
http://www.hindawi.com
Pain
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Toxins
Journal of
Vaccines
Journal of
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Antibiotics
International Journal of
Toxicology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Stroke
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Drug Delivery
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in 
Pharmacological 
Sciences
Tropical Medicine
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Medicinal Chemistry
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Addiction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Emergency Medicine 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Autoimmune 
Diseases
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anesthesiology 
Research and Practice
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Pharmaceutics
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
